O-019 Initial clinical experience with a novel mechanical thrombectomy device-the thrombX retriever

ConclusionThis preliminary study suggests the ThrombX Retriever is safe and has a high rate of substantial reperfusion. A larger prospective trial to assess the device effectiveness is planned.Disclosures D. Behme: 2; C; Thromb X Medical, Phenox, Penumbra, Balt, Vesalio, Acandis. M. Wiesmann: 1; C; Stryker Neurovascular. 2; C; Stryker Neurovascular. 6; C; AB Medica, Acandis, Cerenovus, Kaneka Pharmaceuticals, Medtronic, Mentice AB, Phenox, Philips Healthcare, Stryker Neurovascular. O. Nikoubashman: 1; C; Stryker Neurovascular. 6; C; Phenox, Stryker Neurovascular. H. Ridwan: 2; C; ThrombX Medical. D. Hassan: None. T. Liebig: None. C. Trumm: None. M. Holtmannspötter: 2; C; Microvention, Phenox, Medtronic. 6; C; Cerenovus, Rapid Medical, Microvention, Stryker. M. Marks: 4; C; ThrombX Medical. 5; C; ThrombX Medical. I. Szikora: 1; C; Stryker Neurovascular, Medtronic, Cerenovus. 2; C; Stryker Neurovascular, Medtronic, Cerenovus.

Source: Journal of NeuroInterventional Surgery - July 23, 2022 Category: Neurosurgery Authors: Behme, D., Wiesmann, M., Nikoubashman, O., Ridwan, H., Hassan, D., Liebig, T., Trumm, C., Holtmannspötter, M., Marks, M., Szikora, I. Tags: SNIS 19th annual meeting oral abstracts Source Type: research